Response to 'Lack of efficacy of dupilumab in the treatment of keloid disorder' by MH Tirgan and J Uitto

J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e122-e123. doi: 10.1111/jdv.17699. Epub 2021 Oct 5.

Authors

E Guttman-Yassky¹, A Diaz¹, A B Pavel¹, K Tan¹, H He¹, H Xu¹, I Cueto², J G Krueger²

Affiliations

¹ Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.

PMID: 34551164
DOI: 10.1111/jdv.17699

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Dermatitis, Atopic*
Humans
Keloid* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
dupilumab